---All---
  • ---All---
  • Accession
  • Catalog #

ENOA Antibody (N-term) Blocking PeptideSynthetic peptide

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
BP2879a 0.1 mg 400 ul In Stock $ 45.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

ENOA Antibody (N-term) Blocking Peptide - Product info

Primary AccessionP06733
Clone Names81020035
Calculated MW47169 Da

ENOA Antibody (N-term) Blocking Peptide - Additional info

Gene ID 2023
Target/Specificity
The synthetic peptide sequence used to generate the antibody AP2879a was selected from the N-term region of human ENOA. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Format
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ENOA Antibody (N-term) Blocking Peptide - Protein Information

Name ENO1
Synonyms ENO1L1, MBPB1, MPB1
Function
Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various processes such as growth control, hypoxia tolerance and allergic responses. May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons. Stimulates immunoglobulin production
Cellular Location
Cytoplasm. Cell membrane. Cytoplasm, myofibril, sarcomere, M line. Note=Can translocate to the plasma membrane in either the homodimeric (alpha/alpha) or heterodimeric (alpha/gamma) form. ENO1 is localized to the M line
Tissue Location
The alpha/alpha homodimer is expressed in embryo and in most adult tissues. The alpha/beta heterodimer and the beta/beta homodimer are found in striated muscle, and the alpha/gamma heterodimer and the gamma/gamma homodimer in neurons

ENOA Antibody (N-term) Blocking Peptide - Related products

AP2879a: ENOA Antibody (N-term)

AP2879b: ENOA Antibody (C-term)

AP6526c: ENO1 Antibody (Center)

RI11775: ENO1 predesign siRNA

LY10917a: ENO1 Over-expression Lysate

BP2879a: ENOA Antibody (N-term) Blocking Peptide

BP2879b: ENOA Antibody (C-term) Blocking Peptide

BP6526a: ENO1 Antibody (N-term) Blocking Peptide

BP6526c: ENO1 Antibody (Center) Blocking Peptide

AT1908a: ENO1 Antibody (monoclonal) (M01)

AT1909a: ENO1 Antibody (monoclonal) (M03)

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

ENO1 is one of three enolase isoenzymes found in mammals; the protein alpha-enolase, a homodimeric soluble enzyme, and is also a shorter monomeric structural lens protein, tau-crystallin. The two proteins are made from the same message. The full length protein, the isoenzyme, is found in the cytoplasm. The shorter protein is produced from an alternative translation start, is localized to the nucleus, and has been found to bind to an element in the c-myc promoter.

REFERENCES

Cappello,P., Int. J. Cancer 125 (3), 639-648 (2009)Wygrecka,M., Blood 113 (22), 5588-5598 (2009)